Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia | Zendy

KA Foon | Zendy; J Zighelboim | Zendy; C Yale | Zendy; Gale Rp | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia

Author(s) -

KA Foon,

J Zighelboim,

C Yale,

Gale Rp

Publication year - 1981

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.v58.3.467.bloodjournal583467

Subject(s) - cytarabine , medicine , daunorubicin , chemotherapy , leukemia , regimen , chemotherapy regimen , gastroenterology , complete remission , acute leukemia , surgery

One-hundred and seven patients with acute myelogenous leukemia (AML) ranging in age from 15 to 82 yr who were previously untreated, received a 70 day high-dose remission induction regimen consisting of daunorubicin, cytarabine, and thioguanine (TAD). Identical complete remission rates of 65% were observed for 33 patients 60 yr of age and older and for 74 patients age 15-59 yr. Median remission duration and survival were 14 mo and 22 mo for patients 60 yr and older, and 16 mo and 22 mo for patients 15-59 yr. These differences are not significant. These data indicate that older patients respond to intensive chemotherapy in a similar manner to younger patients with this disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research